Oleg Nadashkevich

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial

Désirée van der Heijde, Xenofon Baraliakos, Lianne S. Gensler et al. · The Lancet · 2018 · 256 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +7

A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis

Oleg Nadashkevich, Paul J. Davis, Marvin J. Fritzler et al. · Clinical Rheumatology · 2005 · 181 citations

Medicine, Pharmacology, Pharmacotherapy +6

A proposal of criteria for the classification of systemic sclerosis.

Oleg Nadashkevich, Paul J. Davis, Marvin J. Fritzler · PubMed · 2004 · 58 citations

Life Sciences, Clinical Sciences, Pathology +17

Efficacy of Tofacitinib for the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis in Patient Subgroups from Two Randomised Phase 3 Trials.

Kim Papp, Jennifer Cather, Craig Leonardi et al. · PubMed · 2016 · 22 citations

Medicine, Dermatology, Pharmacology +12

Patients with rheumatoid arthritis facing sick leave or work disability meet varying regulations: a study among rheumatologists and patients from 44 European countries

Polina Putrik, Sofía Ramiro, Françis Guillemin et al. · Annals of the Rheumatic Diseases · 2019 · 12 citations · Full text

Public Affairs, Health Policy, Disability Policy +13